1
|
Casas-Arozamena C, Moiola CP, Vilar A, Bouso M, Cueva J, Cabrera S, Sampayo V, Arias E, Abalo A, García Á, Lago-Lestón RM, Oltra S, Díaz E, Ruiz-Bañobre J, López-López R, Moreno-Bueno G, Gil-Moreno A, Colás E, Abal M, Muinelo-Romay L. Noninvasive detection of microsatellite instability in patients with endometrial cancer. Int J Cancer 2023; 152:2206-2217. [PMID: 36650670 DOI: 10.1002/ijc.34435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Revised: 12/07/2022] [Accepted: 12/16/2022] [Indexed: 01/19/2023]
Abstract
The analysis of mismatch repair proteins in solid tissue is the standard of care (SoC) for the microsatellite instability (MSI) characterization in endometrial cancer (EC). Uterine aspirates (UAs) or circulating-DNA (cfDNA) samples capture the intratumor heterogeneity and provide a more comprehensive and dynamic molecular diagnosis. Thus, MSI analysis by droplet-digital PCR (ddPCR) in UAs and cfDNA can provide a reliable tool to characterize and follow-up the disease. The UAs, paraffin-embedded tumor tissue (FFPE) and longitudinal plasma samples from a cohort of 90 EC patients were analyzed using ddPCR panel and compared to the SoC. A high concordance (96.67%) was obtained between the analysis of MSI markers in UAs and the SoC. Three discordant cases were validated as unstable by ddPCR on FFPE samples. Besides, a good overall concordance (70.27%) was obtained when comparing the performance of the ddPCR assay on UAs and cfDNA in high-risk tumors. Importantly, our results also evidenced the value of MSI analysis to monitor the disease evolution. MSI evaluation in minimally invasive samples shows great accuracy and sensitivity and provides a valuable tool for the molecular characterization and follow-up of endometrial tumors, opening new opportunities for personalized management of EC.
Collapse
Affiliation(s)
- Carlos Casas-Arozamena
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
- Department of Medicine, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - Cristian Pablo Moiola
- Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain
| | - Ana Vilar
- Gynecology Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - Marta Bouso
- Pathology Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - Juan Cueva
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
- Medical Oncology Department, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - Silvia Cabrera
- Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain
| | - Victoria Sampayo
- Gynecology Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - Efigenia Arias
- Gynecology Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - Alicia Abalo
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - Ángel García
- Pathology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - Ramón Manuel Lago-Lestón
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - Sara Oltra
- Translational Research Group, Foundation MD Anderson International, Madrid, Spain
| | - Eva Díaz
- Translational Research Group, Foundation MD Anderson International, Madrid, Spain
| | - Juan Ruiz-Bañobre
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
- Medical Oncology Department, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
- Genomes and Disease, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago de Compostela, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Rafael López-López
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
- Medical Oncology Department, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Gema Moreno-Bueno
- Translational Research Group, Foundation MD Anderson International, Madrid, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Biochemistry Department, Medicine Faculty, Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - Antonio Gil-Moreno
- Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Gynecology Department, Vall Hebron University Hospital, Barcelona, Spain
| | - Eva Colás
- Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Miguel Abal
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Laura Muinelo-Romay
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| |
Collapse
|
2
|
Gil-Moreno A, Alonso-Alconada L, Díaz-Feijoo B, Domingo S, Vilar A, Hernández A, Gilabert J, Llueca A, Torné A, de Santiago J, Carbonell-Socias M, Lago V, Arias E, Sampayo V, Siegrist J, Chipirliu A, Sánchez-Iglesias JL, Pérez-Benavente A, Padilla-Iserte P, Santacana M, Matias-Guiu X, Abal M, Lopez-Lopez R. M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients. Gynecol Oncol 2021; 161:681-686. [PMID: 33795131 DOI: 10.1016/j.ygyno.2021.03.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Accepted: 03/19/2021] [Indexed: 10/21/2022]
Abstract
OBJECTIVE Despite radical surgery and chemotherapy, most patients with ovarian cancer die due to disease progression. M-Trap is an implantable medical device designed to capture peritoneal disseminated tumor cells with the aim to focalize the disease. This trial analyzed the safety and performance of the device. METHODS This first-in-human prospective, multi-center, non-blinded, single-arm study enrolled 23 women with high-grade serous advanced ovarian cancer. After primary or interval debulking surgery, 3 M-Trap devices were placed in the peritoneum of the abdominal cavity. 18-months post-implantation or at disease progression, devices were initially removed by laparoscopy. The primary safety endpoint was freedom from device and procedure-related major adverse events (MAEs) through 6-months post-implantation compared to an historical control. The primary performance endpoint was histopathologic evidence of tumor cells capture. RESULTS Only one major adverse event was attributable to the device. 18 women were free of device and procedure related MAEs (78.3%). However, the primary safety endpoint was not achieved (p = 0.131), primarily attributable to the greater surgical complexity of the M-Trap patient population. 62% of recurrent patients demonstrated tumor cell capture in at least one device with a minimal tumor cell infiltration. No other long-term device-related adverse events were reported. The secondary performance endpoint demonstrated a lack of disease focalization. CONCLUSIONS The M-Trap technology failed to meet its primary safety objective, although when adjusted for surgical complexity, the study approved it. Likewise, the devices did not demonstrate the anticipated benefits in terms of tumor cell capture and disease focalization in recurrent ovarian cancer.
Collapse
Affiliation(s)
- Antonio Gil-Moreno
- Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, CIBERONC, Barcelona, Spain.
| | | | - Berta Díaz-Feijoo
- Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, CIBERONC, Barcelona, Spain
| | - Santiago Domingo
- Department of Gynecology Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - Ana Vilar
- Department of Gynecology, University Hospital of Santiago de Compostela, Spain
| | - Alicia Hernández
- Department of Gynecology, University Hospital La Paz, Madrid, Spain
| | - Juan Gilabert
- Department of Obstetrics and Gynecology, Hospital General Universitario de Valencia, Universidad de Valencia, Valencia, Spain
| | - Antoni Llueca
- Department of Obstetrics and Gynecology, Hospital General Universitari de Castelló, Castelló de la Plana, Spain
| | - Aureli Torné
- Institute Clinic of Gynecology, Obstetrics and Neonatology, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain
| | | | - Melchor Carbonell-Socias
- Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, CIBERONC, Barcelona, Spain
| | - Víctor Lago
- Department of Gynecology Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - Efigenia Arias
- Department of Gynecology, University Hospital of Santiago de Compostela, Spain
| | - Victoria Sampayo
- Department of Gynecology, University Hospital of Santiago de Compostela, Spain
| | - Jaime Siegrist
- Department of Gynecology, University Hospital La Paz, Madrid, Spain
| | - Anca Chipirliu
- Department of Obstetrics and Gynecology, Hospital General Universitario de Valencia, Universidad de Valencia, Valencia, Spain
| | - Jose Luis Sánchez-Iglesias
- Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, CIBERONC, Barcelona, Spain
| | - Assumpció Pérez-Benavente
- Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, CIBERONC, Barcelona, Spain
| | - Pablo Padilla-Iserte
- Department of Gynecology Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - Maria Santacana
- Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, CIBERONC, Lleida, Spain
| | - Xavier Matias-Guiu
- Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, CIBERONC, Lleida, Spain
| | - Miguel Abal
- Nasasbiotech, S.L., A Coruña, Spain; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), CIBERONC, Santiago de Compostela, Spain
| | - Rafael Lopez-Lopez
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), CIBERONC, Santiago de Compostela, Spain.
| |
Collapse
|
3
|
Martínez-Ordoñez A, Seoane S, Avila L, Eiro N, Macía M, Arias E, Pereira F, García-Caballero T, Gómez-Lado N, Aguiar P, Vizoso F, Perez-Fernandez R. POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation. Oncogene 2021; 40:2725-2740. [PMID: 33714987 PMCID: PMC8049871 DOI: 10.1038/s41388-021-01740-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Revised: 02/19/2021] [Accepted: 02/25/2021] [Indexed: 01/31/2023]
Abstract
Metabolic reprogramming is considered hallmarks of cancer. Aerobic glycolysis in tumors cells has been well-known for almost a century, but specific factors that regulate lactate generation and the effects of lactate in both cancer cells and stroma are not yet well understood. In the present study using breast cancer cell lines, human primary cultures of breast tumors, and immune deficient murine models, we demonstrate that the POU1F1 transcription factor is functionally and clinically related to both metabolic reprogramming in breast cancer cells and fibroblasts activation. Mechanistically, we demonstrate that POU1F1 transcriptionally regulates the lactate dehydrogenase A (LDHA) gene. LDHA catalyzes pyruvate into lactate instead of leading into the tricarboxylic acid cycle. Lactate increases breast cancer cell proliferation, migration, and invasion. In addition, it activates normal-associated fibroblasts (NAFs) into cancer-associated fibroblasts (CAFs). Conversely, LDHA knockdown in breast cancer cells that overexpress POU1F1 decreases tumor volume and [18F]FDG uptake in tumor xenografts of mice. Clinically, POU1F1 and LDHA expression correlate with relapse- and metastasis-free survival. Our data indicate that POU1F1 induces a metabolic reprogramming through LDHA regulation in human breast tumor cells, modifying the phenotype of both cancer cells and fibroblasts to promote cancer progression.
Collapse
Affiliation(s)
- Anxo Martínez-Ordoñez
- grid.11794.3a0000000109410645Department of Physiology-Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Santiago de Compostela, Spain ,grid.5386.8000000041936877XPresent Address: Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY USA
| | - Samuel Seoane
- grid.11794.3a0000000109410645Department of Physiology-Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Leandro Avila
- grid.11794.3a0000000109410645Department of Physiology-Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Noemi Eiro
- Research Unit, Hospital Fundación de Jove, Gijón, Spain
| | - Manuel Macía
- grid.488911.d0000 0004 0408 4897Department of Obstetrics and Gynecology, Health Research Institute of Santiago de Compostela (IDIS)-University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Efigenia Arias
- grid.488911.d0000 0004 0408 4897Department of Obstetrics and Gynecology, Health Research Institute of Santiago de Compostela (IDIS)-University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Fabio Pereira
- grid.488911.d0000 0004 0408 4897Department of Radiation Oncology, Health Research Institute of Santiago de Compostela (IDIS)-University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Tomas García-Caballero
- grid.488911.d0000 0004 0408 4897Department of Morphological Sciences, Health Research Institute of Santiago de Compostela (IDIS)-University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Noemi Gómez-Lado
- grid.11794.3a0000000109410645Molecular Imaging Group. Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, and Health Research Institute of Santiago de Compostela (IDIS). University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Pablo Aguiar
- grid.11794.3a0000000109410645Molecular Imaging Group. Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, and Health Research Institute of Santiago de Compostela (IDIS). University of Santiago de Compostela, Santiago de Compostela, Spain
| | | | - Román Perez-Fernandez
- grid.11794.3a0000000109410645Department of Physiology-Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Santiago de Compostela, Spain
| |
Collapse
|
4
|
Casas-Arozamena C, Díaz E, Moiola CP, Alonso-Alconada L, Ferreiros A, Abalo A, López Gil C, Oltra SS, de Santiago J, Cabrera S, Sampayo V, Bouso M, Arias E, Cueva J, Colas E, Vilar A, Gil-Moreno A, Abal M, Moreno-Bueno G, Muinelo-Romay L. Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer. J Clin Med 2020; 9:E585. [PMID: 32098121 PMCID: PMC7073542 DOI: 10.3390/jcm9020585] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Revised: 02/04/2020] [Accepted: 02/19/2020] [Indexed: 12/17/2022] Open
Abstract
The incidence and mortality of endometrial cancer (EC) have risen in recent years, hence more precise management is needed. Therefore, we combined different types of liquid biopsies to better characterize the genetic landscape of EC in a non-invasive and dynamic manner. Uterine aspirates (UAs) from 60 patients with EC were obtained during surgery and analyzed by next-generation sequencing (NGS). Blood samples, collected at surgery, were used for cell-free DNA (cfDNA) and circulating tumor cell (CTC) analyses. Finally, personalized therapies were tested in patient-derived xenografts (PDXs) generated from the UAs. NGS analyses revealed the presence of genetic alterations in 93% of the tumors. Circulating tumor DNA (ctDNA) was present in 41.2% of cases, mainly in patients with high-risk tumors, thus indicating a clear association with a more aggressive disease. Accordingly, the results obtained during the post-surgery follow-up indicated the presence of ctDNA in three patients with progressive disease. Moreover, 38.9% of patients were positive for CTCs at surgery. Finally, the efficacy of targeted therapies based on the UA-specific mutational landscape was demonstrated in PDX models. Our study indicates the potential clinical applicability of a personalized strategy based on a combination of different liquid biopsies to characterize and monitor tumor evolution, and to identify targeted therapies.
Collapse
Affiliation(s)
- Carlos Casas-Arozamena
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (C.C.-A.); (A.A.); (J.C.); (M.A.)
| | - Eva Díaz
- Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain; (E.D.); (S.S.O.); (G.M.-B.)
| | - Cristian Pablo Moiola
- Biomedical Research Group in Gynecology, Vall d’Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain; (C.P.M.); (S.C.); (E.C.); (A.G.-M.)
| | | | - Alba Ferreiros
- Nasasbiotech, S.L., Canton Grande 3, 15003 A Coruña, Spain; (L.A.-A.); (A.F.)
| | - Alicia Abalo
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (C.C.-A.); (A.A.); (J.C.); (M.A.)
| | - Carlos López Gil
- Biomedical Research Group in Gynecology, Vall d’Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain; (C.P.M.); (S.C.); (E.C.); (A.G.-M.)
| | - Sara S. Oltra
- Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain; (E.D.); (S.S.O.); (G.M.-B.)
| | - Javier de Santiago
- Department of Gynecology, MD Anderson Cancer Center, 28029 Madrid, Spain;
| | - Silvia Cabrera
- Biomedical Research Group in Gynecology, Vall d’Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain; (C.P.M.); (S.C.); (E.C.); (A.G.-M.)
| | - Victoria Sampayo
- Department of Gynecology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (V.S.); (E.A.); (A.V.)
| | - Marta Bouso
- Department of Pathology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain;
| | - Efigenia Arias
- Department of Gynecology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (V.S.); (E.A.); (A.V.)
| | - Juan Cueva
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (C.C.-A.); (A.A.); (J.C.); (M.A.)
| | - Eva Colas
- Biomedical Research Group in Gynecology, Vall d’Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain; (C.P.M.); (S.C.); (E.C.); (A.G.-M.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - Ana Vilar
- Department of Gynecology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (V.S.); (E.A.); (A.V.)
| | - Antonio Gil-Moreno
- Biomedical Research Group in Gynecology, Vall d’Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain; (C.P.M.); (S.C.); (E.C.); (A.G.-M.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - Miguel Abal
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (C.C.-A.); (A.A.); (J.C.); (M.A.)
- Nasasbiotech, S.L., Canton Grande 3, 15003 A Coruña, Spain; (L.A.-A.); (A.F.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - Gema Moreno-Bueno
- Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain; (E.D.); (S.S.O.); (G.M.-B.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain
- Department of Biochemistry, Autonomic University of Madrid (UAM), Biomedical research Institute ‘Alberto Sols’ (CSIC-UAM), IdiPaz, Arzobispo Morcillo 4, 28029 Madrid, Spain
| | - Laura Muinelo-Romay
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (C.C.-A.); (A.A.); (J.C.); (M.A.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain
| |
Collapse
|
5
|
Dong S, Aguirre-Hernandez C, Scrivo A, Eliscovich C, Arias E, Bravo-Cordero JJ, Cuervo AM. Monitoring spatiotemporal changes in chaperone-mediated autophagy in vivo. Nat Commun 2020; 11:645. [PMID: 32005807 PMCID: PMC6994528 DOI: 10.1038/s41467-019-14164-4] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Accepted: 12/06/2019] [Indexed: 02/07/2023] Open
Abstract
Autophagy malfunctioning occurs in multiple human disorders, making attractive the idea of chemically modulating it with therapeutic purposes. However, for many types of autophagy, a clear understanding of tissue-specific differences in their activity and regulation is missing because of lack of methods to monitor these processes in vivo. Chaperone-mediated autophagy (CMA) is a selective type of autophagy that until now has only been studied in vitro and not in the tissue context at single cell resolution. Here, we develop a transgenic reporter mouse that allows dynamic measurement of CMA activity in vivo using image-based procedures. We identify previously unknown spatial and temporal differences in CMA activity in multiple organs and in response to stress. We illustrate the versatility of this model for monitoring CMA in live animals, organotypic cultures and cell cultures from these mice, and provide practical examples of multiorgan response to drugs that modulate CMA.
Collapse
Affiliation(s)
- S Dong
- Department of Development and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA
- Institute for Aging Studies, Albert Einstein College of Medicine, Bronx, NY, 10461, USA
| | - C Aguirre-Hernandez
- Department of Development and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA
- Institute for Aging Studies, Albert Einstein College of Medicine, Bronx, NY, 10461, USA
- Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, 10029, NY, USA
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, 10029, NY, USA
| | - A Scrivo
- Department of Development and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA
- Institute for Aging Studies, Albert Einstein College of Medicine, Bronx, NY, 10461, USA
| | - C Eliscovich
- Department of Medicine Marion Liver Research Center, Albert Einstein College of Medicine, Bronx, 10461, NY, USA
| | - E Arias
- Institute for Aging Studies, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
- Department of Medicine Marion Liver Research Center, Albert Einstein College of Medicine, Bronx, 10461, NY, USA.
| | - J J Bravo-Cordero
- Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, 10029, NY, USA.
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, 10029, NY, USA.
| | - A M Cuervo
- Department of Development and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
- Institute for Aging Studies, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
- Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, 10029, NY, USA.
| |
Collapse
|
6
|
Reich E, Torres C, Halac E, Arias E, Pless S. Compromise of self awareness and disease perception in multiple sclerosis. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Zavanella T, Arias E, Zaffaroni NP. Preliminary Study on the Carcinogenic Activity of the Fungicide Manganese Ethylenebisdithiocarbamate in the Adult Newt, Triturus Cristatus Carnifex. Tumori 2018; 65:163-7. [PMID: 462568 DOI: 10.1177/030089167906500204] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Percutaneous exposure of adult newts to the fungicide manganese ethylenebisdithiocarbamate (maneb) at 3 concentration levels (0.5, 2.5 and 5.0 ppm) for a total of 19-23 weeks did not result in the induction of any neoplasms.
Collapse
|
8
|
Flores J, Pérez F, Jiménez-Barrera R, Arias E, Moggio I, Torres R, Rodríguez G, Ottonelli M, Ziolo R. Synthesis and photophysical properties of ferrocene -oligo(benzoateethynylene)- fulleropyrrolidines dyads and triads. Implications in photovoltaic cells. J Organomet Chem 2018. [DOI: 10.1016/j.jorganchem.2018.02.040] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
9
|
Reich E, Torres C, Arias E, Carlino M, Halac E, Ceruzzi R. Alzheimer´s disease: Is stress a potential risk factor? J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
10
|
Vilardell P, Canal E, Berenguel M, Paz Bermejo M, Arias E, Loma-Osorio P, Brugada R. P2494Long-term benefits of cardiac rehabilitation: a three-year follow-up study. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Arias E, Florez E, Pérez–Torres JF. Algorithm based on the Thomson problem for determination of equilibrium structures of metal nanoclusters. J Chem Phys 2017; 146:244107. [DOI: 10.1063/1.4984049] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Affiliation(s)
- E. Arias
- Facultad de Ciencias Básicas, Universidad de Medellín, Medellín, Colombia
| | - E. Florez
- Facultad de Ciencias Básicas, Universidad de Medellín, Medellín, Colombia
| | - J. F. Pérez–Torres
- Facultad de Ciencias Básicas, Universidad de Medellín, Medellín, Colombia
- Escuela de Qumica, Universidad Industrial de Santander, Bucaramanga, Colombia
| |
Collapse
|
12
|
|
13
|
Seoane S, Arias E, Sigueiro R, Sendon-Lago J, Martinez-Ordoñez A, Castelao E, Eiró N, Garcia-Caballero T, Macia M, Lopez-Lopez R, Maestro M, Vizoso F, Mouriño A, Perez-Fernandez R. Pit-1 inhibits BRCA1 and sensitizes human breast tumors to cisplatin and vitamin D treatment. Oncotarget 2016; 6:14456-71. [PMID: 25992773 PMCID: PMC4546479 DOI: 10.18632/oncotarget.3894] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2015] [Accepted: 04/25/2015] [Indexed: 11/25/2022] Open
Abstract
The POU class 1 homeobox 1 (POU1F1, also known as Pit-1), pertaining to the Pit-Oct-Unc (POU) family of transcription factors, has been related to tumor growth and metastasis in breast. However, its role in response to breast cancer therapy is unknown. We found that Pit-1 down-regulated DNA-damage and repair genes, and specifically inhibited BRCA1 gene expression, sensitizing breast cancer cells to DNA-damage agents. Administration of 1α, 25-dihydroxy-3-epi-vitamin D3 (3-Epi, an endogenous low calcemic vitamin D metabolite) reduced Pit-1 expression, and synergized with cisplatin, thus, decreasing cell proliferation and apoptosis in vitro, and reducing tumor growth in vivo. In addition, fifteen primary cultures of human breast tumors showed significantly decreased proliferation when treated with 3-Epi+cisplatin, compared to cisplatin alone. This response positively correlated with Pit-1 levels. Our findings demonstrate that high levels of Pit-1 and reduced BRCA1 levels increase breast cancer cell susceptibility to 3-Epi+cisplatin therapy.
Collapse
Affiliation(s)
- Samuel Seoane
- Department of Physiology, University of Santiago de Compostela, Santiago de Compostela 15782, Spain.,Center for Research in Molecular Medicine and Chronic Diseases-CIMUS, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Efigenia Arias
- Center for Research in Molecular Medicine and Chronic Diseases-CIMUS, University of Santiago de Compostela, Santiago de Compostela 15782, Spain.,Department of Obstetrics and Gynecology, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Rita Sigueiro
- Department Organic Chemistry, Research Laboratory Ignacio Rivas, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Juan Sendon-Lago
- Department of Physiology, University of Santiago de Compostela, Santiago de Compostela 15782, Spain.,Center for Research in Molecular Medicine and Chronic Diseases-CIMUS, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Anxo Martinez-Ordoñez
- Department of Physiology, University of Santiago de Compostela, Santiago de Compostela 15782, Spain.,Center for Research in Molecular Medicine and Chronic Diseases-CIMUS, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Esteban Castelao
- Oncology and Genetics Unit, Biomedical Research Institute of Vigo (IBIV), Complejo Hospitalario Universitario de Vigo, Servicio Galego de Saude (SERGAS), Vigo 36036, Spain
| | - Noemí Eiró
- Research Unit, Fundación Hospital de Jove, Gijón 33290, Spain
| | - Tomás Garcia-Caballero
- Department of Morphological Sciences, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Manuel Macia
- Department of Obstetrics and Gynecology, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Rafael Lopez-Lopez
- Department of Clinical Oncology, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Miguel Maestro
- Department Organic Chemistry, Research Laboratory Ignacio Rivas, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | | | - Antonio Mouriño
- Department Organic Chemistry, Research Laboratory Ignacio Rivas, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Roman Perez-Fernandez
- Department of Physiology, University of Santiago de Compostela, Santiago de Compostela 15782, Spain.,Center for Research in Molecular Medicine and Chronic Diseases-CIMUS, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| |
Collapse
|
14
|
|
15
|
Neira M, Lopez Doriga P, Arias E, Gomez Cerezo J, Bielza R. P-220: Prognostic factors related to functional recovery after hip fracture. Eur Geriatr Med 2015. [DOI: 10.1016/s1878-7649(15)30318-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
16
|
Gutiérrez A, Vázquez R, Moggio I, Arias E, Coreño O, Maldonado J, Ramos-Ortíz G, Rodríguez O, Jiménez-Barrera R. Mechanosynthesis of a phenylenedivinylidenebisquinoline. Optical, morphological and electroluminescence properties. J Mol Struct 2015. [DOI: 10.1016/j.molstruc.2015.01.019] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Meza D, Arias E, Moggio I, Romero J, Mata JM, Jiménez-Barrera RM, Ziolo RF, Rodríguez O, Ottonelli M. Synthesis and photophysical and supramolecular study of π-conjugated (diethylene glycol methyl ether) benzoateethynylene oligomers and polymers. Polym Chem 2015. [DOI: 10.1039/c4py01516a] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The strong π–π interaction that governs (diethylene glycol methyl ether) benzoateethynylene macromolecules was evidenced by X-ray scattering and HRTEM.
Collapse
Affiliation(s)
- D. Meza
- Centro de Investigación en Química Aplicada (CIQA)
- Saltillo
- México
| | - E. Arias
- Centro de Investigación en Química Aplicada (CIQA)
- Saltillo
- México
| | - I. Moggio
- Centro de Investigación en Química Aplicada (CIQA)
- Saltillo
- México
| | - J. Romero
- Centro de Investigación en Química Aplicada (CIQA)
- Saltillo
- México
| | - J. M. Mata
- Centro de Investigación en Química Aplicada (CIQA)
- Saltillo
- México
| | | | - R. F. Ziolo
- Centro de Investigación en Química Aplicada (CIQA)
- Saltillo
- México
| | - O. Rodríguez
- Centro de Investigación en Química Aplicada (CIQA)
- Saltillo
- México
| | - M. Ottonelli
- Dipartimento di Chimica e Chimica Industriale
- Universitá di Genova
- 16146 Genoa
- Italy
| |
Collapse
|
18
|
Krawitzky M, Arias E, Peiro J, Negueruela A, Val J, Oria R. Determination of Color, Antioxidant Activity, and Phenolic Profile of Different Fruit Tissue of Spanish ‘Verde Doncella’ Apple Cultivar. International Journal of Food Properties 2014. [DOI: 10.1080/10942912.2013.792829] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
19
|
|
20
|
Arias E. American Society for Bone and Mineral Research 2013 Annual Meeting (ASBMR), Baltimore, Maryland, USA - October 4-7, 2013. DRUG FUTURE 2013. [DOI: 10.1358/dof.2013.038.11.2086177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Querri A, Ohkado A, Poblete R, Agujo P, Tang F, Arias E, Medina A, Mantala M, Vianzon R, Lagahid J, Shimouchi A. Tuberculosis Diagnostic Committees' contribution to the National TB Program in Manila and Quezon Cities. Public Health Action 2012; 2:82-6. [PMID: 26392958 DOI: 10.5588/pha.12.0006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2012] [Accepted: 06/28/2012] [Indexed: 11/10/2022] Open
Abstract
SETTING The Philippines Tuberculosis Diagnostic Committees (TBDCs) were created to improve the quality of diagnosis of sputum smear-negative chest radiography suggestive of pulmonary tuberculosis (sn-PTB). OBJECTIVE To determine current TBDC activities, obstacles and possible solutions for improvements in the quality of diagnosis of sn-PTB in Manila City and Quezon City. DESIGN A descriptive review of TBDC Masterlist records and interviews with TBDC members using a semi-structured questionnaire. RESULTS A record review of nine of 10 TBDCs was conducted, with interviews of 33 of the 49 current members. During the second and third quarters of 2009, respectively 1142 and 1563 sn-PTB cases were evaluated by the TBDCs in both cities. Of these, 53% in Manila City and 65% in Quezon City were classified as active TB patients. There were significant variations in the percentage of patients recommended for anti-tuberculosis treatment by the TBDC. The participation of its members is based on their expressed commitment to program sustainability. CONCLUSION TBDC activities contribute to TB control in the Philippines by ensuring the judicious use of resources. Further research to assess the contributions of TBDCs in reducing diagnostic and treatment delays, and factors affecting the sustainability of the TBDCs, is recommended.
Collapse
Affiliation(s)
- A Querri
- Research Institute of Tuberculosis/Japan Anti-Tuberculosis Association Philippines, Inc., Manila, The Philippines
| | - A Ohkado
- Research Institute of Tuberculosis/Japan Anti-Tuberculosis Association Philippines, Inc., Manila, The Philippines
| | - R Poblete
- Research Institute of Tuberculosis/Japan Anti-Tuberculosis Association Philippines, Inc., Manila, The Philippines
| | - P Agujo
- Manila City Health Department, Manila, The Philippines
| | - F Tang
- Quezon City Health Department, Quezon, The Philippines
| | - E Arias
- Quezon City Health Department, Quezon, The Philippines
| | - A Medina
- Center for Health Development, National Capital Region, Department of Health, Mandaluyong, The Philippines
| | - M Mantala
- Research Institute of Tuberculosis/Japan Anti-Tuberculosis Association Philippines, Inc., Manila, The Philippines
| | - R Vianzon
- National Center for Disease Control and Prevention, Department of Health, Manila, The Philippines
| | - J Lagahid
- National Center for Disease Control and Prevention, Department of Health, Manila, The Philippines
| | - A Shimouchi
- Research Institute of Tuberculosis/Japan Anti-Tuberculosis Association Philippines, Inc., Manila, The Philippines
| |
Collapse
|
22
|
Reich E, Arias E, Kerszberg M. Anosognosia and Multiple Sclerosis (P02.037). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p02.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
23
|
|
24
|
|
25
|
Arias E, Vasiliou S, Cole P. Highlights from the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2011: Visionary Genomics. DRUG FUTURE 2011. [DOI: 10.1358/dof.2011.036.12.1727785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
26
|
|
27
|
Mougel D, Arias E, Hirlet S, Gomez E, Chabot F. « LEGENDAIR », Société COVIDIEN (AIROX). Rev Mal Respir 2009; 26:904-5. [DOI: 10.1016/s0761-8425(09)73687-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
Giorgetti E, Giusti A, Arias E, Moggio I, Ledezma A, Romero J, Saba M, Quochi F, Marceddu M, Gocalinska A, Mura A, Bongiovanni G. In Situ Production of Polymer-Capped Silver Nanoparticles for Optical Biosensing. ACTA ACUST UNITED AC 2009. [DOI: 10.1002/masy.200950922] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
29
|
Mougel D, Arias E, Kheir A, Guillaumot A, Chabot F. « HELIA 2 », Société RESMED (SAIME). Rev Mal Respir 2009; 26:681-2. [DOI: 10.1016/s0761-8425(09)74698-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
30
|
Arias E, González A, Shimada A, Varela-Echavarria A, Ruiz-López F, During A, Mora O. β-Carotene is incorporated or mobilized along with triglycerides in bovine adipose tissue in response to insulin or epinephrine. J Anim Physiol Anim Nutr (Berl) 2009; 93:83-93. [DOI: 10.1111/j.1439-0396.2007.00783.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Gonzalez J, Arias E, Salvador M, Oria R. Modeling of Changes in Atmosphere Composition in Fresh-cut Peach Packages due to Temperature Fluctuations. FOOD SCI TECHNOL INT 2008. [DOI: 10.1177/1082013208095326] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Storage temperature is not always constant in the distribution chain of modified atmosphere fresh food packages. A change in temperature means an alteration in the respiration rate of the product and in the gas transmission rates through the film. Because of their high metabolic activity, minimally processed products are particularly sensitive to temperature variation, and hence this study has been carried out with five cultivars of fresh-cut peaches (Prunus persica). Their respiratory activity has been determined by a closed system at 4, 15, and 25 °C. The peach segments are wrapped in microperforated films whose transmission rate is determined according to the size of the microperforations (between 100 × 130 μm and 215 × 190 μm). To quantify the effect of temperature fluctuations (5 h at 25 °C) on the O2 and CO2 concentrations of the packaging atmosphere of the product, a mathematical model has been applied. Using experimental data, it has been established that the rate of O2 consumption is a potential function of the O2 concentration, while the production of CO2 is linear. Although, all cultivars are of nonmelting fresh with no big differences in respiratory activity; these differences are accentuated with O2 concentrations greater than 10% and raising the temperature. The solution of the model provides knowledge of the behavior of the product during its nonstationary period and equilibrium once reached. The results show in all cases that the CO 2 concentration is more sensitive (increase of 5 units) to a break in the cold chain than that of O2 (reduction of 2 units).
Collapse
Affiliation(s)
- J. Gonzalez
- Laboratory of Vegetal Food, University of Zaragoza,
Miguel Servet 177, 50013 Zaragoza, Spain
| | - E. Arias
- Laboratory of Vegetal Food, University of Zaragoza,
Miguel Servet 177, 50013 Zaragoza, Spain
| | - M.L. Salvador
- Laboratory of Vegetal Food, University of Zaragoza,
Miguel Servet 177, 50013 Zaragoza, Spain,
| | - R. Oria
- Laboratory of Vegetal Food, University of Zaragoza,
Miguel Servet 177, 50013 Zaragoza, Spain
| |
Collapse
|
32
|
Núñez LM, Muggeri A, Arias E, Taratuto AL, Sevlever G, Diez B, Martinetto H. EGFR/AKT pathways alterations in gliomas. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Arias E, González J, Peiró JM, Oria R, Lopez-Buesa P. Browning Prevention by Ascorbic Acid and 4-Hexylresorcinol: Different Mechanisms of Action on Polyphenol Oxidase in the Presence and in the Absence of Substrates. J Food Sci 2007; 72:C464-70. [DOI: 10.1111/j.1750-3841.2007.00514.x] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Arias E, González J, Oria R, Lopez-Buesa P. Ascorbic Acid and 4-Hexylresorcinol Effects on Pear PPO and PPO Catalyzed Browning Reaction. J Food Sci 2007; 72:C422-9. [DOI: 10.1111/j.1750-3841.2007.00484.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Dominguez-Chávez JG, Lijanova I, Moggio I, Arias E, Vazquez-Garcia RA, Reyes-Valderrama Ma I, Klimova T, Gutierrez-Nava M, Martínez-García M. Synthesis of fluorescent dendrimers with an oligo(phenylenevinylene) core. J Nanosci Nanotechnol 2007; 7:2758-66. [PMID: 17685294 DOI: 10.1166/jnn.2007.616] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Novel fluorescent dendrimers of first, second, and third generation bearing a conjugated oligo(phenylenevinylene) (OPV) core and peripherial allyl chains as dendrons have been synthesized by a convergent method. The compounds have been fully characterized by 1H, 13C NMR, FTIR, UV-vis, and fluorescence spectroscopy, MALDI-TOF or FAB+ mass spectroscopy and elemental analysis. All dendrimers showed in solution a blue fluorescence with a maximum wavelength at 444-446 nm and can be deposited as thin films emitting in the blue-green region. The most homogeneous films were obtained for the second generation dendrimer which also exhibits the higher quantum yield in solution. These properties make it a possible candidate for application in organic light emitting diodes (OLEDs).
Collapse
Affiliation(s)
- J G Dominguez-Chávez
- Instituto de Quimica, UNAM, Ciudad Universitaria, Circuito Exterior, CP 04510, México DF, Mexico
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Varón R, Minaya-Pacheco MA, García-Molina F, Arribas E, Arias E, Masiá J, García-Sevilla F. Competitive and uncompetitive inhibitors simultaneously acting on an autocatalytic zymogen activation reaction. J Enzyme Inhib Med Chem 2007; 21:635-45. [PMID: 17252936 DOI: 10.1080/14756360600858562] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
The time course of the residual enzyme activity of a general model consisting of an autocatalytic zymogen activation process inhibited by an irreversible competitive inhibitor and an irreversible uncompetitive inhibitor has been studied. Approached analytical expressions which furnish the time course of the residual enzyme activity from the onset of the reaction depending on the rate constants and initial concentration have been obtained. The goodness and limitations of the analytical equations were checked by comparing with the results obtained from the numerical integration, i.e. with the simulated progress curves. A dimensionless parameter giving the relative contributions of both the activation and the inhibitions routes is suggested, so that the value of this parameter determines whether the activation or the inhibitions routes prevail or if both processes are balanced during the time for which the analytical expressions are valid. The effects of the initial zymogen, free enzyme and inhibitors concentrations are analysed. Finally an experimental design and kinetic data analysis is proposed to evaluate simultaneously the kinetic parameters involved and to discriminate between different zymogen activation processes which can be considered particular cases of the general model.
Collapse
Affiliation(s)
- R Varón
- Departamento de Química-Física, Escuela Politécnica Superior de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain.
| | | | | | | | | | | | | |
Collapse
|
37
|
Hernández Fernaud J, Carnicero A, Perestelo F, Hernández Cutuli M, Arias E, Falcón M. Upgrading of an industrial lignin by using laccase produced by Fusarium proliferatum and different laccase-mediator systems. Enzyme Microb Technol 2006. [DOI: 10.1016/j.enzmictec.2005.01.043] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
38
|
YangI. Dı́az C, Arias E, Leal J, Remohi J, Garcia-Velasco J. Fresh vs frozen testicular sperm: The experience from 1142 cycles. Fertil Steril 2004. [DOI: 10.1016/j.fertnstert.2004.07.446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
39
|
Hoyert DL, Arias E, Smith BL, Murphy SL, Kochanek KD. Deaths: final data for 1999. Natl Vital Stat Rep 2001; 49:1-113. [PMID: 11591077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
OBJECTIVES This report presents final 1999 data on U.S. deaths and death rates according to demographic and medical characteristics. Trends and patterns in general mortality, life expectancy, and infant and maternal mortality are also described. A previous report presented preliminary mortality data for 1999. METHODS In 1999 a total of 2,391,399 deaths were reported in the United States. This report presents tabulations of information reported on the death certificates completed by funeral directors, attending physicians, medical examiners, and coroners. Original records are filed in the State registration offices. Statistical information is compiled into a national data base through the Vital Statistics Cooperative Program of the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention. For the first time in a final mortality data report, age-adjusted death rates are based upon the year 2000 population and causes of death are processed in accordance with the Tenth Revision of the International Classification of Diseases (ICD-10). RESULTS The 1999 age-adjusted death rate for the United States was 881.9 deaths per 100,000 standard population, a 0.7 percent increase from the 1998 rate, and life expectancy at birth remained the same at 76.7 years. For all causes of death, age-specific death rates rose for those 45-54 years, 75-84 years, and 85 years and over and declined for a number of age groups including those 5-14 years, 55-64 years, and 65-74 years. Aortic aneurysm and dissection made its debut in the list of leading causes of death and atherosclerosis exited from the list. Heart disease and cancer continued to be the leading and second leading causes of death. The age-adjusted death rate for firearm injuries decreased for the sixth consecutive year, declining 6.2 percent between 1998 and 1999. The infant mortality rate, 7.1 infant deaths per 1,000 live births, was not statistically different from the rate in 1998. CONCLUSIONS Generally, mortality continued long-term trends. Life expectancy in 1999 was unchanged from 1998 despite a slight increase in the age-adjusted death rate from the record low achieved in 1998. Although statistically unchanged from 1998, the trend in infant mortality has been of a steady but slowing decline. Some mortality measures for women and persons 85 years and over worsened between 1998 and 1999.
Collapse
|
40
|
Affiliation(s)
- E Arias
- Dipartimento di Biologia, Università degli Studi di Milano, Via G. Celoria 26, I-20133 Milano, Italy.
| |
Collapse
|
41
|
Jiménez JJ, Bernal JL, del Nozal MJ, Toribio L, Arias E. Analysis of pesticide residues in wine by solid-phase extraction and gas chromatography with electron capture and nitrogen-phosphorus detection. J Chromatogr A 2001; 919:147-56. [PMID: 11459301 DOI: 10.1016/s0021-9673(01)00632-x] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
A feasible and reproducible method for multiresidue analysis of several common pesticides, of different polarities, in wine samples is proposed. The method combines a solid-phase extraction on polymeric cartridges eluted with ethyl acetate and a gas chromatographic determination using electron capture and nitrogen-phosphorus detection. To avoid the matrix effect, previous washing of the cartridges with a mixture of water-2-propanol (90:10) and further clean-up of the extract on Florisil cartridges, together with a calibration using spiked extracts, are recommended.
Collapse
Affiliation(s)
- J J Jiménez
- Department of Analytical Chemistry, Faculty of Sciences, University of Valladolid, Spain
| | | | | | | | | |
Collapse
|
42
|
Fabbro De Suasnábar D, Arias E, Streiger M, Piacenza M, Ingaramo M, Del Barco M, Amicone N. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo 2000; 42:99-109. [PMID: 10810325 DOI: 10.1590/s0036-46652000000200007] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The aim of this work was to compare the evolution of chronic chagasic untreated patients (UTPs) with that of benznidazole or nifurtimox-treated patients (TPs). A longitudinal study from a low endemic area (Santa Fe city, Argentina) was performed during an average period of 14 years. Serological and parasitological analyses with clinical exams, ECG and X-chest ray were carried out. At the onset, 19/198 infected patients showed chagasic cardiomyopathy (CrChM) while 179 were asymptomatic. In this latter group the frequency of CrChM during the follow-up was lower in TPs compared with UTPs (3.2% vs 7%). Within the CrChM group, 2/5 TPs showed aggravated myopathy whereas this happened in 9/14 UTPs. Comparing the clinical evolution of all patients, 5.9% of TPs and 13% of UTPs had unfavourable evolution, but the difference is not statistically relevant. Serological titers were assessed by IIF. Titers equal to or lower than 1/64 were obtained in 86% of the TPs, but only in 38% of UTPs. The differences were statistically significant (geometric mean: 49.36 vs. 98.2). Antiparasitic assessment of the drugs (xenodiagnosis) proved to be effective. The low sensitivity in chronic chagasic patients must be born in mind. Despite treated patients showed a better clinical evolution and lower antibody levels than untreated ones, it is necessary to carry on doing research in order to improve therapeutic guidelines, according to the risk/benefit equation and based on scientific and ethical principles.
Collapse
Affiliation(s)
- D Fabbro De Suasnábar
- Centro de Investigaciones sobre Endemias Nacionales, Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina.
| | | | | | | | | | | | | |
Collapse
|
43
|
Grimm DR, Arias E, Lesser M, Bauman WA, Almenoff PL. Airway hyperresponsiveness to ultrasonically nebulized distilled water in subjects with tetraplegia. J Appl Physiol (1985) 1999; 86:1165-9. [PMID: 10194198 DOI: 10.1152/jappl.1999.86.4.1165] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The majority of otherwise healthy subjects with chronic cervical spinal cord injury (SCI) demonstrate airway hyperresponsiveness to aerosolized methacholine or histamine. The present study was performed to determine whether ultrasonically nebulized distilled water (UNDW) induces airway hyperresponsiveness and to further elucidate potential mechanisms in this population. Fifteen subjects with SCI, nine with tetraplegia (C4-7) and six with paraplegia (T9-L1), were initially exposed to UNDW for 30 s; spirometry was performed immediately and again 2 min after exposure. The challenge continued by progressively increasing exposure time until the forced expiratory volume in 1 s decreased 20% or more from baseline (PD20) or the maximal exposure time was reached. Five subjects responding to UNDW returned for a second challenge 30 min after inhalation of aerosolized ipratropium bromide (2.5 ml of a 0.6% solution). Eight of nine subjects with tetraplegia had significant bronchoconstrictor responses to UNDW (geometric mean PD20 = 7.76 +/- 7.67 ml), whereas none with paraplegia demonstrated a response (geometric mean PD20 = 24 ml). Five of the subjects with tetraplegia who initially responded to distilled water (geometric mean PD20 = 5.99 +/- 4.47 ml) were not responsive after pretreatment with ipratropium bromide (geometric mean PD20 = 24 ml). Findings that subjects with tetraplegia are hyperreactive to UNDW, a physicochemical agent, combined with previous observations of hyperreactivity to methacholine and histamine, suggest that overall airway hyperresponsiveness in these individuals is a nonspecific phenomenon similar to that observed in patients with asthma. The ability of ipratropium bromide to completely block UNDW-induced bronchoconstriction suggests that, in part, airway hyperresponsiveness in subjects with tetraplegia represents unopposed parasympathetic activity.
Collapse
Affiliation(s)
- D R Grimm
- Spinal Cord Damage Research Center, Veterans Affairs Medical Center, Bronx 10468, New York, New York 10029, USA.
| | | | | | | | | |
Collapse
|
44
|
Cabeza M, Miranda R, Arias E, Diaz de Leon L. Inhibitory effect of propranolol on lipid synthesis in gonadectomized male hamster flank organs. Arch Med Res 1999; 29:291-5. [PMID: 9887545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
BACKGROUND This paper describes the inhibitory effect produced by propranolol pre-treatment on lipid synthesis in flank organs from intact, gonadectomized, and isoproterenol-treated male hamsters. Furthermore, the effect induced by the same treatments on gland sebum composition is reported. METHODS Different groups of male hamsters were injected daily with propranolol, isoproterenol or propranolol plus isoproterenol. Treatment-effect was evaluated determining the in vitro incorporation of radioactive acetate into lipids in hamster flank organs from intact and castrated animals. Additionally, radiolabeled lipids were isolated and identified using TLC and autoradiography as methods. RESULTS Results demonstrate that castration significantly decreases lipid synthesis in male hamster flank organs. In addition, propranolol treatment inhibits such synthesis in glands from intact, gonadectomized, and isoproterenol-treated animals. However, isoproterenol treatment was ineffective when compared to intact or gonadectomized control vehicle-treated animals. Lipid classes isolated and identified lipids either in castrated or in drug-treated animals were phospholipids, cholesterol, monoglycerides, fatty acids, waxes and cholesterol esters. CONCLUSIONS Results indicate an inhibitory effect induced on lipid synthesis by beta-adrenergic receptor antagonists; however, beta-adrenergic agonists drugs do not stimulate it. Data suggest a permissive role of adrenergic hormones on lipid synthesis in intact and in gonadectomized animals. Furthermore, castration decreased the synthesis, suggesting that a tight coupling between beta-adrenergic receptors and androgen receptors may be a prerequisite for lipogenesis in this tissue. Pre-treatment does not modify sebum composition in gonadectomized animal glands. These data support the evidence that activation of beta-adrenergic receptors could be an independent factor in the lipid composition regulation process.
Collapse
Affiliation(s)
- M Cabeza
- Departamentos de Sistemas Biológicos y de Producción Agrícola y Animal, Universidad Autónoma Metropolitana-Xochimilco, México, D.F.
| | | | | | | |
Collapse
|
45
|
Affiliation(s)
- E Arias
- Dipartimento di Biologia, Universitá degli Studi di Milano, Italy
| |
Collapse
|
46
|
Zavanella T, Radaelli G, Girotti P, Arias E, Ameri L, Presta M, Mazzoleni G, Ragnotti G. Evaluation of the tumor-promoting activity of two beta-adrenoreceptor blocking agents, propranolol and atenolol, in liver of Fischer 344 rats. Carcinogenesis 1994; 15:2531-9. [PMID: 7955102 DOI: 10.1093/carcin/15.11.2531] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
The tumor-promoting activity of two beta-adrenoreceptor blocking agents, propranolol and atenolol, was tested in a two-stage protocol of hepatocarcinogenesis in male and female Fischer 344 rats. Propranolol is a lipophilic non-selective beta-blocker mainly eliminated via the liver; atenolol is a hydrophilic beta 1-selective blocking agent, mainly eliminated via the kidney. Animals were initiated with a single dose of diethylnitrosamine (DEN, 200 mg/kg, i.p.) and, after 17 days of recovery, were continuously treated with propranolol (75-100 mg/kg) or atenolol (300 mg/kg) by gavage for up to 21 months. Rats given phenobarbital (0.05% in the diet) were used as positive controls. After 2, 4 and 8 months of promotion, preneoplastic lesions were quantified by staining sections of liver for gamma-glutamyltranspeptidase (GGT). In non-initiated rats, neither propranolol nor atenolol influenced the development of spontaneous preneoplastic or neoplastic liver lesions. The results obtained in DEN-initiated rats given propranolol cannot be unequivocally interpreted. In the male, propranolol seemed to be ineffective. In the female, there was weak enhancement of DEN-induced GGT foci at 4 and 8 months and of neoplastic lesions thereafter. However, there was great interindividual variability in focus and tumor yields. Unfortunately, due to the high incidence of liver tumors in rats given DEN alone and the small number of propranolol-treated rats that survived until the end of the experiment, no definite conclusion can be drawn about the modifying potential of this beta-blocker on liver carcinogenesis. There was no evidence of liver tumor promotion in DEN-initiated rats of either sex given atenolol.
Collapse
Affiliation(s)
- T Zavanella
- Department of Biology, Faculty of Science, University of Milan, Italy
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Miranda-Ruiz R, Castañón-González J, Pérez Aldana C, Arias E, Díaz de León Ponce M, Zárate A. [Effect of a synthetic somatostatin analogue with delayed action (SMS 201-995) on the biliary expenditure in a patient with an external biliary tract fistula]. Rev Gastroenterol Mex 1990; 55:67-9. [PMID: 2287871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The effect of treatment with a long acting analogue of somatostatin (SMS 201-995) administered by subcutaneous route 165 micrograms every eight hours in a patient with a external biliary fistula is reported. There was a significant reduction of the daily fistula output during treatment when compared with the basal periods (p = 0.04), with an average decrease of 270 ml/day during the first period of treatment and 357 ml/day when the drug was administered the second time (p = 0.04). There where not changes in the chemical composition of the bile neither adverse side effects were observed during treatment. These results suggest that SMS 201-995 might be useful in the treatment of external biliary fistulas.
Collapse
Affiliation(s)
- R Miranda-Ruiz
- Unidad de Investigación de Endocrinología, IMSS, México, D.F
| | | | | | | | | | | |
Collapse
|
48
|
Santagostino A, Colleoni M, Arias E, Pacces Zaffaroni N, Zavanella T. Changes in catalase, glutathione peroxidase and glutathione-S-transferase activities in the liver of newts exposed to 2-methyl-4-chlorophenoxyacetic acid (MCPA). Pharmacol Toxicol 1989; 65:136-9. [PMID: 2813285 DOI: 10.1111/j.1600-0773.1989.tb01143.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Activities of catalase, glutathione peroxidase (GSH-Px) and glutathione-S-transferase (GST) were measured in livers of the crested newt (Urodele Amphibian) after 16 days of percutaneous exposure to the herbicide Agroxone 3, a commercial formulation of 2-methyl-4-chlorophenoxyacetic acid (MCPA) containing 25% MCPA as sodium salt and 75% wetting and dispersing ingredients. Animals of both sexes were exposed to 800 p.p.m. of the active ingredient. There was a three-fold increase in catalase and a clear enhancement of GSH-Px in the MCPA-exposed animals of both sexes. A sex-dependent effect of MCPA was observed on GST activity, which increased significantly in female newts only. Similar liver enzyme changes were observed in female newts, and not in males, given the hypolipidaemic drug clofibrate (13 mg/animal/day, by gavage, for 8 days), which is structurally related to phenoxyherbicides. These findings indicate that the crested newt is sensitive to the hepatic effects of the peroxisome proliferators.
Collapse
Affiliation(s)
- A Santagostino
- Institute of Pharmacology, University of Milano, Faculty of Science MMFFNN, Italy
| | | | | | | | | |
Collapse
|
49
|
El-tonsi H, Gable H, Arias E, Behr HZ. Changing trends in conception control. Adv Contracept Deliv Syst 1989; 5:35-47. [PMID: 12315699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/19/2023]
|
50
|
Abstract
The genotoxic potential of a commercial formulation of the fungicide maneb (Maneb 80, containing 80% manganese ethylenebisdithiocarbamate as active ingredient) in chick embryos was evaluated, using as genetic end-points the frequency of sister-chromatid exchanges (SCE) and of chromosomal aberrations. Unincubated eggs were dipped in 0, 0.5, 1.5, 4.5, 13.5 or 27 g/l maneb aqueous solutions for 30 sec. Eggs were then incubated for 4 days. Maneb significantly increased SCE values at 13.5 g/l and at 27 g/l (means 1.33 and 1.74) over the control value (mean 0.87). The concentration of 27 g/l, which corresponds to 10.8 times the recommended maximum application level for use in the field, also resulted in a high mortality rate. No clastogenic effects following exposure to maneb were observed.
Collapse
Affiliation(s)
- E Arias
- Dipartimento di Biologia, Università di Milano, Italy
| |
Collapse
|